Navigation Links
eResearchTechnology Reports First Quarter 2008 Results
Date:5/5/2008

.1 million, compared to $29.7 million for the

first quarter of 2007;

-- Bookings included seven new Thorough ECG study agreements valued at an

average of slightly greater than $1 million each;

-- The backlog was a record $151.4 million, a net increase of

$11.2 million from December 31, 2007;

-- The cancellation rate was an annualized 15.6% as compared to an

annualized cancellation rate of 15.0% in the first quarter of 2007.

"We are extremely pleased with the first quarter results where we saw record quarterly revenue, transactions, bookings and backlog for eRT," commented Dr. Michael McKelvey, President and CEO of eRT. "We continue to execute very well on our projects. The integration of the CCSS acquisition is proceeding on schedule, and we are meeting with clients to begin the transition process of individual studies. Our services revenue grew by 80.9%, driven by outstanding growth in our core cardiac safety business. Bookings were strong across all phases, but especially in Phase I and Phase III studies. The quarter again demonstrated the leverage in our business model as evidenced by expanding gross margins and net income growth."

The Company reported revenues of $33.7 million for the first quarter of 2008, an increase of 59.7% from $21.1 million in the first quarter of 2007. Net income was $5.7 million for the first quarter of 2008, an increase of 155.6% from $2.2 million for the first quarter of 2007. Diluted net income per share was $0.11 for the first quarter of 2008, up $0.07 from the $0.04 in the first quarter of 2007.

eRT ended the quarter with $48.9 million in cash, cash equivalents and investments, an increase of $2.0 million from $46.9 million at December 31, 2007. Operations generated $7.6 million, which was partially offset by payments to Covance under the terms of the CCSS acquisition.

"Our pipeline of new opportunities is strong, reflecting the continued emphasis on c
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
2. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
6. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. MannKind Corporation Reports First Quarter Financial Results
9. Verenium Reports Financial Results for the First Quarter 2008
10. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
11. United Therapeutics Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... EAST HANOVER, N.J. , June 1, 2015 ... Phase II clinical study of CTL019, an investigational ... indicate its potential in the treatment of specific ... ongoing study conducted by the University of Pennsylvania,s ... relapsed or refractory (r/r) diffuse large B-cell lymphoma ...
(Date:6/1/2015)... 1, 2015  The Val Skinner Foundation is partnering ... curriculum for high school students focused on cancer genetics. ... annual LIFE Event (LPGA Pros in the Fight to ... in West Caldwell, N.J. ... raised more than $500,000 on Monday, bringing the foundation,s ...
(Date:6/1/2015)... , May 29, 2015 Research ... addition of the "Global Bioinformatics Market 2015-2019" ... analysts forecast the global bioinformatics market to grow ... 2014-2019. Bioinformatics is a field of science ... consists of information stored in DNA form and ...
(Date:6/1/2015)... , June 1, 2015  Boston-based Veritas ... genetic testing industry and bring personalized medicine and ... more control of their health. Beginning with its ... and ovarian cancer risk, Veritas Genetics is making ... exponentially expanding the amount of genetic data which ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Val Skinner Foundation Announces Partnership With Discovery Education 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3
... 2 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... Phase 3 clinical study of fidaxomicin in patients with ... by clinical investigator, Mark A. Miller, M.D., at the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , ...
... DIEGO, June 2 Amylin Pharmaceuticals, Inc. (Nasdaq: ... the independent Inspector of Elections for the Company,s Annual ... its preliminary tabulation of shareholder votes. The preliminary ... the Company,s current Directors to Amylin,s Board of Directors ...
... event at Walsh College ... seekers networking event , , TROY, Mich., June 2 ... Services have teamed up to offer a new series of Walsh College,s ... round of workshops features more days, more topics and expanded career content. ...
Cached Biology Technology:Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 2Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 4Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 5Amylin Announces Preliminary Tabulation of Annual Meeting Results 2Amylin Announces Preliminary Tabulation of Annual Meeting Results 3Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 2Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 3Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 4
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... countless coral reefs around the world can now be nabbed ... say. Coral researchers and reef managers will be able ... them to classify specific diseases based on the presence of ... reduce the impact of disease on the world,s imperilled coral ...
... Alto, CA--The four largest nonprofit plant science research institutions ... Association of Independent Plant Research Institutes (AIPI) in an ... profound challenges facing society in a more coordinated and ... Thompson Institute for Plant Research (Cornell University), The Carnegie ...
... for athletes looking to boost performance comes in the form ... reason for its popularity is twofold says Scott Forbes, a ... precursor for nitric oxide that is known to improve blood ... nutrients to working muscles and assist with metabolic waste product ...
Cached Biology News:Scientific sleuths pinpoint the guilty coral killers 2Big boost to plant research 2Big boost to plant research 3L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3
... pending) is a protein based inhibitor of ... the most common and troublesome RNases including ... SUPERaseIn can be used in any application ... is ideal for in vitro transcription and ...
... The ChIP (Chemical Inkjet Printer) is ... Mass Fingerprinting and Protein Macroarray Analysis, ... company, ProteomeSystems. The strategy compliments established ... gels (using the proteins isoelectric point ...
...
... Immunogen: synthetic peptide corresponding to the ... dopamine receptor, conjugated to KLH. The ... rat and mouse gene. Physical form: ... containing 0.01% sodium azide. Titertest method: ...
Biology Products: